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ABSTRACT 23 
    A major difference between vaccine and wild-type strains of measles virus (MV) 24 
in vitro is the wider cell specificity of vaccine strains, resulting from the receptor usage 25 
of the hemagglutinin (H) protein.  Wild-type H proteins recognize the signaling 26 
lymphocyte activation molecule (SLAM; CD150), which is expressed on certain cells 27 
of the immune system, whereas vaccine H proteins recognize CD46, which is 28 
ubiquitously expressed on all nucleated human and monkey cells, in addition to SLAM.  29 
To examine the effect of the H protein on tropism and attenuation of MV, we generated 30 
enhanced green fluorescent protein (EGFP)-expressing recombinant wild-type MV 31 
strains bearing the Edmonston vaccine H protein (MV-EdH) and compared them to 32 
EGFP-expressing wild-type MV strains.  In vitro, MV-EdH replicated in SLAM(+) as 33 
well as CD46(+) cells, including primary cell cultures from cynomolgus monkey 34 
tissues, whereas the wild-type MV replicated in only SLAM(+) cells.  However, in 35 
macaques, both wild-type MV and MV-EdH strains infected lymphoid and respiratory 36 
organs, and wide spread infection of MV-EdH was not observed.  Flow cytometric 37 
analysis indicated that SLAM(+) lymphocyte cells were infected preferentially with 38 
both strains.  Interestingly, EGFP expression of MV-EdH in tissues and lymphocytes 39 
was significantly weaker than that of the wild-type MV.  Taken together, these results 40 
indicate that the CD46-binding activity of the vaccine H protein is important for 41 
determining the cell specificity of MV in vitro but not the tropism in vivo.  They also 42 
suggest that the vaccine H protein attenuates the MV growth in vivo. 43 
INTRODUCTION 44 
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  Measles remains a major cause of childhood morbidity and mortality worldwide 45 
especially in developing countries in spite of significant progress in global measles 46 
control programs.  Measles virus (MV), belonging to the genus Morbillivirus of the 47 
family Paramyxoviridae, is an enveloped virus with a non-segmented negative-strand 48 
RNA genome (11).  The MV genome encodes 6 structural proteins: the nucleocapsid 49 
(N), phospho (P), matrix (M), fusion (F), hemagglutinin (H), and large (L) proteins.  50 
Two envelope glycoproteins, the F and H proteins, initiate infection of the target cells 51 
via binding of the H protein to its cellular receptors.  Therefore, the H protein is of 52 
primarily importance for determining the cell specificity of MV (22).  53 
  The Edmonston strain of MV was isolated in 1954 by using a primary culture of 54 
human kidney cells (7).  The Edmonston strain was subsequently adapted in a variety 55 
of cells, including chicken embryo fibroblasts to enable the production of attenuated 56 
live vaccines, which are currently used worldwide (27).  These live, attenuated MV 57 
strains are safe and induce strong cellular and humoral immune responses against MV.  58 
The Edmonston vaccine strain is no longer pathogenic in monkey models (2, 7, 37, 39).  59 
In contrast, wild-type MV strains isolated and passaged in B95a cells induce clinical 60 
signs resembling those of human measles in experimentally infected cynomolgus and 61 
rhesus monkeys (15, 16).  62 
  A major difference between vaccine and MV wild-type strains in vitro is their cell 63 
specificity.  Vaccine strains of MV grow efficiently in many human and primate cell 64 
lines, whereas wild-type strains of MV grow only in limited lymphoid cell lines.  This 65 
difference is attributed mainly to the receptor usage of MV strains.  The H proteins of 66 
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wild-type strains recognize the signaling lymphocyte activation molecule (SLAM; also 67 
called CD150), which is expressed in certain immune system cells (36), and recently 68 
identified nectin-4 (also called PVRL4), which is expressed in epithelial cells in 69 
trachea, skin, lung, prostate and stomach as a cellular receptor (20, 23).  However, the 70 
H proteins of MV vaccine strain recognize CD46 (6, 21) in addition to SLAM and 71 
nectin-4 as cellular receptors.  Since CD46 is expressed in all human and monkey 72 
nucleated cells, MV vaccine strains can grow in many human and primate cell lines.  73 
Indeed, when the H protein of a wild-type strain of MV was exchanged with that of an 74 
MV vaccine strain, the resulting recombinant wild-type MV strain grew in many 75 
human and monkey cell lines (12, 28, 35). 76 
  Although the receptor specificity of the H proteins of MV strains has been studied 77 
extensively, very little is known about the effect of the H protein on the in vivo tropism 78 
and attenuation of MV.  Given the H proteins of MV vaccine strains can use CD46 in 79 
addition to SLAM and nectin-4 as cellular receptors, recombinant MV strains bearing 80 
the H protein of MV vaccine strains may have an expanded in vivo tropism.   81 
  In this study, we generated enhanced green fluorescent protein (EGFP)-expressing 82 
recombinant wild-type strains of MV bearing the H protein of the Edmonston MV 83 
vaccine strain by using our reverse genetics system (32) and compared the cell 84 
specificity in vitro and tropism in vivo with those of EGFP-expressing MV wild-type 85 
strains.  We found that the H protein of the Edmonston vaccine strain of MV alters the 86 
cell specificity of the MV wild-type strain in vitro but does not alter the tropism of the 87 
MV wild-type strain in vivo.  Furthermore, the H protein of the Edmonston vaccine 88 
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strain attenuates the MV growth in macaques.  89 
 90 
MATERIALS AND METHODS 91 
Cells and viruses 92 
  B95a cells (an adherent marmoset B-cell line transformed with Epstein-Barr virus) 93 
(15) were maintained in Dulbecco’s modified essential medium (DMEM) 94 
supplemented with 10% fetal bovine serum (FBS).  Chinese hamster ovary (CHO) 95 
cells constitutively expressing human SLAM (CHO/hSLAM) (29) were maintained in 96 
Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% FBS 97 
and 500 µg of G418 per ml.  Primary cynomolgus monkey astroglial cells were 98 
obtained from Nobuyuki Kimura (National Institute of Biomedical Innovation, 99 
Tsukuba, Japan).  IC323-EGFP was obtained from Yusuke Yanagi (Kyushu University, 100 
Fukuoka, Japan) (12).  Vaccinia virus vTF7-3 encoding T7 RNA polymerase was 101 
obtained from Bernard Moss (National Institute of Health, Bethesda, MD) (9). 102 
 103 
Preparation of primary cynomolgus monkey kidney cells 104 
  The kidneys of a cynomolgus monkey were removed, sliced into small pieces, and 105 
digested with 0.3% trypsin in Hanks’ balanced salt solution (HBBS) at 37˚C with 106 
continuous stirring for an appropriate period.  The dispersed cells were collected and 107 
washed twice with HBBS.  The cells were suspended in DMEM supplemented with 108 
10% FCS, seeded on a plate, and incubated at 37˚C.  Cells that grew as a monolaye r 109 
culture were passaged, and the cells at passages 3 to 5 were used in the experiments. 110 
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 111 
Construction of full-length cDNAs and reverse genetics 112 
  Plasmid p(+)MV323, carrying the full-genome cDNA of the IC-B strain has been 113 
described previously (15, 32, 33).  Plasmid p(+)MV017, carrying the full-genome 114 
cDNA of the IC-B strain containing the H gene of the Edmonston B strain (Z66517), 115 
has been described previously (35).  To exchange the H gene of p(+)MV323-EGFP 116 
with that of the Ed strain, a PacI-SpeI fragment containing the H gene was excised 117 
from p(+)MV323-EGFP and replaced with the corresponding fragment from 118 
p(+)MV017 resulting in p(+)MV017-EGFP.  To introduce the EGFP gene between 119 
the F and H genes of p(+)MV323 and p(+)MV017, the open reading frame of an 120 
enhanced green fluorescent protein (EGFP) gene was first amplified from pEGFP-N1 121 
(Clontech, Mountain View, CA) by using the primers 122 
5’-ATCAGGGACAAGAGCAGGATTAGGGATATCCGAGATGGTGAGCAAGGGC123 
GAGGA -3’ and 124 
5’-GATGTTGTTCTGGTCCTCGGCCTCTCGCACTTACTTGTACAGCTCGTCCA-125 
3’ and then using the primers 126 
5’-GCGTTAATTAAAACTTAGGATTCAAGATCCTATTATCAGGGACAAGAGCA127 
GGAT-3’ and 128 
5’-GCGTTAATTAACAATGATGGAGGGTAGGCGGATGTTGTTCTGGTCCTCGG-129 
3’ to introduce a PacI recognition site (underlined).  After digestion with PacI, the 130 
EGFP fragment was inserted into the PacI site in p(+)MV323 and p(+)MV017, 131 
resulting in p(+)MV323-EGFP(F/H) and p(+)MV017-EGFP(F/H), respectively.  132 
  7 
Recombinant MV strains, EdH-EGFP, IC323-EGFP2 and EdH-EGFP2, were generated 133 
from p(+)MV017-EGFP, p(+)MV323-EGFP(F/H) and p(+)MV017-EGFP(F/H) 134 
plasmids, respectively, by using CHO/hSLAM cells and a vaccinia virus vTF7-3 as 135 
reported previously (29).  IC323-EGFP, EdH-EGFP, IC323-EGFP2, and EdH-EGFP2 136 
were propagated in B95a cells, and virus stocks at 3-4 passages in B95a cells were 137 
used for experiments.  The amino acid sequence of the F protein of the IC-B strains 138 
(NC_001498/AB016162) is identical to that of the Edmonston-B strain (Z66517).  139 
 140 
Infection of cynomolgus monkeys with recombinant MVs 141 
  Cynomolgus monkeys were inoculated intranasally with 105 times the 50% tissue 142 
culture infective dose (TCID50) of IC323-EGFP2 or EdH-EGFP2 by using a nasal spray 143 
(Keytron, Chiba, Japan).  Three animals (#4848, #4849, and #4850) were juvenile (1 144 
year old), and 6 animals (#5056, #5057, #5058, #5062, #5068, and #5069) were of 4-5 145 
years old.  All animals were seronegative for MV.  Peripheral blood mononuclear 146 
cells (PBMCs) were isolated using a Percoll gradient (Amersham, Piscataway, NJ) 147 
diluted with 1.5 M NaCl solution to 1.07 g/ml.  MV-infected cells in PBMCs, spleen 148 
and cervical lymph nodes were counted as previously reported (32).  All animal 149 
experiments were performed in compliance with the guidelines of National Institute of 150 
Infectious Disease (Tokyo, Japan). 151 
 152 
Macroscopic detection of EGFP fluorescence 153 
  EGFP fluorescence in the tissues and organs of cynomolgus monkeys was observed 154 
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using a VB-G25 fluorescence microscope equipped with a VB-7000/7010 155 
charge-coupled device (CCD) detection system (Keyence, Osaka, Japan).  For the 156 
respective excitation and the detection of fluorescence, 470/40 nm and 510 nm 157 
band-pass filters were used.   158 
 159 
Histopathological and immunohistochemical analysis 160 
  Animals were anesthetized, and tissues from lung, bronchi, heart, liver, kidney, skin, 161 
spleen, mesenteric lymph node, cervical lymph node, thymus, salivary gland, tonsil, 162 
stomach, pancreas, and jejunum were fixed with 10% phosphate-buffered formalin.  163 
Fixed tissues were embedded in paraffin, sectioned, and stained with hematoxylin and 164 
eosin.  Immunohistochemical detection of the N protein of MV was performed on 165 
paraffin-embedded sections as described previously (34). 166 
 167 
Double immunofluorescence staining 168 
  Paraffin-embedded lungs were used for staining the N protein of MV and 169 
cytokeratin.  The sections were subjected to a double immunofluorescence staining 170 
method employing a rabbit antiserum against the N protein and the cytokeratin 171 
monoclonal mouse antibody (clone MAB1611, Chemicon, CA).  Briefly, after 172 
deparaffinization with xylene, the sections were re-hydrated in ethanol and immersed 173 
in phosphate buffered saline (PBS).  Antigens were retrieved by hydrolytic 174 
autoclaving for 15 min at 121°C in the retrieval solution at pH 9.0 (Nichirei, Tokyo, 175 
Japan).  After cooling, normal goat serum was used to block background staining.  176 
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The sections were incubated with the anti-cytokeratin antibody for 30 min at 37°C.  177 
After 3 washes in PBS, the sections were incubated with an antiserum against MV N 178 
protein for 30 min at 37°C.  Antigen-binding sites were detected by goat anti-rabbit 179 
Alexa Fluor 488 (Molecular Probes, Eugene, OR) or goat anti-mouse Alexa Fluor 546 180 
(Molecular Probes) for 30 min at 37°C.  The sections were mounted with SlowFade 181 
Gold antifade reagent with DAPI (Molecular Probes), and the images were captured 182 
using a fluorescence microscope (IX71; Olympus, Tokyo, Japan) equipped with a 183 
Hamamatsu high-resolution digital B/W CCD camera (ORCA2; Hamamatsu Photonics, 184 
Hamamatsu, Japan). 185 
 186 
Flow-cytometric analysis 187 
  PBMCs were stained with the following monoclonal antibodies cross-reactive with 188 
macaque cells:  CD150-phycoerythrin (PE) clone A12 (BD Pharmingen, San Diego, 189 
CA), CD3-APC clone SP34-2 (BD Pharmingen) and CD20-PE/Cy7 clone 2H7 190 
(BioLegend, San Diego, CA).  The cells were fixed with 1% paraformaldehyde and 191 
MV-infected cells were detected by the expression of EGFP in the fluorescein 192 
isothiocyanate channel.  The flow cytometric acquisition of approximately 193 
200,000-500,000 events from each sample was performed on FACSCalibur.  194 
 195 
Amplification of MV genomic RNA by real-time reverse transcription polymerase 196 
chain reaction (RT-PCR) 197 
  Total RNA was isolated from tissues by using the RNAlater and RNeasy kit 198 
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(QIAGEN, Hilden, Germany) according to the manufacturer’s protocol, reverse 199 
transcribed and PCR amplified with a Thermal Cycler Dice TP800 (Takara, Tokyo, 200 
Japan) by using FastStart SYBR Green Master (Roche).  For amplification of the MV 201 
genome sequence, MV-P1 primer 5’-AGATGCTGACTCTATCATGG-3’ (positions 202 
2,178-2,197) was used for RT, and then MV-P1 primer and MV-P2 primer 203 
5’-TCGAGCACATTGGGTTGCAC-3’ (position 2,574-2,555) were used for PCR.  204 
For amplification of the 18S RNA segment, the 18S sense primer 205 
TCAAGAACGAAAGTCGGAGG and 18S antisense primer 206 
GGACATCTAAGGGCATCACA (25) were used.  In a separate experiment, we 207 
amplified DNA from a known amount of p(+)MV323-EGFP plasmid containing the 208 
target region under the same reaction conditions, and the results for the real-time 209 
RT-PCR were expressed as genome RNA equivalent to p(+)MV323-EGFP. 210 
 211 
Cytokine assay 212 
  Cytokine levels in the plasma were measured with a Luminex 200 (Luminex, Austin, 213 
TX) by using a Milliplex Non-Human Primate Cytokine/Chemokine kit (Millipore, 214 
Billerica, MA) according to the manufacturer’s instruction.  The assay sensitivities 215 
were as follows; IL-12/23 (p40), 1.11 pg/ml; IFN-γ, 0.30 pg/ml; IL-2, 0.73 pg/ml; IL-4, 216 
1.25 pg/ml; IL-5, 0.26 pg/ml; IL-17, 0.13 pg/ml; IL-6, 0.40 pg/ml; TNF-α, 0.86 pg/ml; 217 
IL-1β, 0.16 pg/ml; and MCP-1, 0.91 pg/ml. 218 
 219 
RESULTS 220 
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Generation of recombinant MV strains expressing EGFP 221 
  To compare cell specificity in vitro of wild-type MV and wild-type MV bearing the 222 
H protein of the Edmonston vaccine strain, we generated EdH-EGFP from wild-type 223 
IC323-EGFP (12).  IC323-EGFP and EdH-EGFP (Fig. 1A) have the EGFP gene 224 
preceding the N gene and induce a strong EGFP fluorescence in infected monolayer 225 
cells.   For in vivo infection, we generated IC323-EGFP2 and EdH-EGFP2 (Fig. 1A) 226 
having the EGFP gene between the F and H genes, because a previous report using 227 
canine distemper virus (CDV) indicated that a CDV strain having the EGFP gene 228 
preceding the N gene reduced the overall CDV gene expression and was less virulent 229 
(38).  IC323-EGFP2 and EdH-EGFP2 induced very weak EGFP fluorescence in 230 
infected monolayer cells (data not shown) because of the polar effect of paramyxovirus 231 
transcription (17).   232 
 233 
Infection of primary cell culture with recombinant MV strains 234 
  We first examined the cell specificity of IC323-EGFP and EdH-EGFP in vitro.  In 235 
B95a cells, both IC323-EGFP and EdH-EGFP induced large syncytia and strong EGFP 236 
expression, whereas in Vero cells, only EdH-EGFP induced syncytia and strong EGFP 237 
expression (Fig. 1B), consistent with our previous observation (35).  Notably, 238 
EdH-EGFP induced large syncytia and strong EGFP expression in primary kidney and 239 
primary astroglial cells derived from cynomolgus monkey tissues (Fig. 1B).  Thus, 240 
the H protein of the Edmonston vaccine strain of MV can expand the in vitro cell 241 
specificity of the wild-type MV strain in established cell lines as well as in primary cell 242 
  12 
cultures of cynomolgus monkey tissues.    243 
   244 
Preliminary infection of cynomolgus monkeys with recombinant MV strains 245 
  We next examined the in vivo tropism and growth of IC323-EGFP2 and EdH-EGFP2 246 
by using 3 cynomolgus monkeys.  Prior to the infection of monkeys with 247 
IC323-EGFP2 and EdH-EGFP2, we examined the in vitro cell specificity of both 248 
strains by using B95a and Vero cells and confirmed that EdH-EGFP2 had the wider in 249 
vitro cell specificity (Fig. 1C).  Then, one monkey (#4850) was inoculated with 250 
IC323-EGFP2, and two monkeys (#4848 and #4849) were inoculated with EdH-EGFP2.  251 
At day 7, viremia was observed in all 3 monkeys (Fig. 2A).  Upon necropsy at day 7, 252 
nearly the same numbers of MV-infected cells were isolated from the cervical lymph 253 
nodes of 3 monkeys (Fig. 2A).  EGFP fluorescence was observed in many lymphoid 254 
tissues, including the cervical lymph nodes, tongue, tonsils, stomach, and 255 
gut-associated lymph nodes in 3 monkeys (Fig. 2B).  No significant difference was 256 
observed in the distribution and intensity of EGFP fluorescence in the internal organs 257 
and tissues among the 3 monkeys, indicating that tropism of EdH-EGFP2 was not 258 
expanded in vivo. 259 
 260 
Growth of recombinant MV strains in cynomolgus monkeys 261 
  To assess whether these results can be confirmed, 6 monkeys were infected with 262 
IC323-EGFP2 or EdH-EGFP2.  Three monkeys (#5058, #5062, and #5069) were 263 
inoculated with IC323-EGFP2, and 3 monkeys (#5056, #5057, and #5068) were 264 
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inoculated with EdH-EGFP2.  At day 7, viremia was detected in all 6 monkeys, and 265 
the number of infected cells was increased at day 10 in most monkeys (Fig. 3A, left).   266 
Upon necropsy at day 10, MV-infected cells were isolated from the cervical lymph 267 
nodes and spleens of 6 monkeys (Fig. 3A, right).  In monkeys infected with 268 
IC323-EGFP2 a large number of the lymphocytes (up to 49%) of cervical lymph nodes 269 
were infected, whereas in monkeys infected with EdH-EGFP2 a smaller number (0.040 270 
to 0.77%) of the lymphocytes of cervical lymph nodes were infected (Fig. 3A, right).  271 
Similarly, in monkeys infected with IC323-EGFP2 a large number of the lymphocytes 272 
(up to 8.2%) in the spleen were infected, whereas in monkeys infected with 273 
EdH-EGFP2 a smaller number (0.032 to 1.5%) of the lymphocytes in cervical lymph 274 
nodes were infected (Fig. 3A, right).  In all 6 monkeys infected with either 275 
IC323-EGFP2 or EdH-EGFP2, substantial amounts of MV genome RNA were detected 276 
in the tonsils, cervical lymph nodes, thymus, spleen, mesenteric lymph nodes, inguinal 277 
lymph nodes, bone marrow, and lungs (Fig. 3B).  We note that the amount of MV 278 
genome RNA of EdH-EGFP2-infected monkeys was significantly lower than that of 279 
IC323-EGFP2-infected monkeys especially in lungs. 280 
 281 
Macroscopic detection of EGFP fluorescence in organs and tissues 282 
  In all 6 monkeys infected by IC323-EGFP2 or EdH-EGFP2, EGFP fluorescence was 283 
macroscopically detected in many lymphoid organs and tissues including the tongue 284 
and tonsils, thymus, trachea and lungs, stomach, and gut-associated lymph nodes, upon 285 
necropsy at day 10 (Fig. 4).  No difference was observed in the distribution of EGFP 286 
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fluorescence in the internal organs and tissues between monkeys infected with 287 
IC323-EGFP2 or EdH-EGFP2, confirming that tropism of EdH-EGFP2 is not expanded 288 
in macaques.  However, the intensity of EGFP fluorescence in the internal organs and 289 
tissues of EdH-EGFP2-infected monkeys was significantly weaker than that of 290 
IC323-EGFP2-infected monkeys. 291 
 292 
Histopathological and immunohistochemical analysis 293 
  To further examine tissue and organ tropism of IC323-EGFP2 and EdH-EGFP2, we 294 
performed histopathological and immunohistochemical analyses of fixed specimens.  295 
In bronchioles, we histopathologically observed bronchiolitis and giant cells with 296 
eosinophilic inclusion bodies in monkeys infected with both IC323-EGFP2 and 297 
EdH-EGFP2, and MV N antigen was detected in both sections (Fig. 5A).  Tissue 298 
sections obtained from the bronchiole area were double-stained with anti-MV N and 299 
anti-cytokeratin antibodies, which clearly showed infection of EdH-EGFP2 to the 300 
epithelial cells (Fig. 5B) as reported for wild-type MV (3, 20), possibly through 301 
nectin-4-mediated pathway (18, 20, 23, 31).  Interestingly, the N protein was 302 
accumulated under the apical plasma membrane of the infected cells (Fig. 5B), 303 
suggesting an intracellular transport mechanism for the N protein to the apical plasma 304 
membrane.  The MV N antigen was detected in the lymphocytes of the spleen, 305 
mesenteric and cervical lymph nodes, thymus, salivary gland, tonsils, stomach, and 306 
jejunum (Table 1), as well as in epithelia of the lungs, bronchi, tonsils, and stomach but 307 
not in the muscles of the heart and in the epithelia of the liver, kidney, skin, tonsils, and 308 
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stomach of most monkeys.  These data again indicated that tropism of EdH-EGFP2 309 
was not expanded in macaques. 310 
 311 
Flow cytometric analysis 312 
  To examine the cell tropism of IC323-EGFP2 and EdH-EGFP2 in lymphocytes, 313 
EGFP expression in lymphocytes isolated from PBMCs and mesenteric lymph nodes 314 
was analyzed by flow cytometry.  0.90% and 8.59% of B lymphocytes in PBMCs and 315 
MLN, respectively, and 0.90% and 3.90% of T lymphocytes in PBMCs and MLN, 316 
respectively, were infected with IC323-EGFP2 (Fig. 6).  Lymphocytes expressing 317 
SLAM were infected with IC323-EGFP2 as previously reported (3).  Similarly, 318 
0.44-0.53% and 1.06-2.23% of B lymphocytes in PBMCs and MLN, respectively, and 319 
0.42-0.68% and 0.70-1.44% of T lymphocytes in PBMCs and MLN, respectively, were 320 
infected with EdH-EGFP2 (Fig. 6).  Lymphocytes expressing SLAM were also 321 
infected with EdH-EGFP2.  These results indicated that tropism of EdH-EGFP2 was 322 
not expanded in lymphocytes of macaques.  Interestingly, the number and intensity of 323 
EGFP-expressing cells in lymphocytes of EdH-EGFP2-infected monkeys were 324 
significantly lower than that of 323-EGFP2-infected monkeys.   325 
 326 
Cytokine production of infected monkeys 327 
  To investigate whether the differences in growth of IC323-EGFP2 and EdH-EGFP2 328 
in monkeys were associated with altered host responses to infection, we measured 329 
cytokine and chemokine levels in the plasma of infected monkeys.  Cytokines 330 
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selected for analysis were IL-12, IFN-γ, IL-2, IL-4, IL-5, and IL-17 (Th1/Th2 balance), 331 
and the IL-6, TNF-α, IL-1β, and MCP-1 (inflammatory response).   332 
  With Th1-type cytokines, we found that plasma levels of IL-12 were high for 3 333 
(#5056, #5057, and #5062) out of 6 monkeys at day 0, slightly elevated at day 3, and 334 
then declined by day 7 (Fig. 7).  The plasma levels of IL-12 for other 3 monkeys 335 
(#5058, #5068, and #5069) were low throughout the experiment.  Irrespective of the 336 
plasma levels of IL-12, the plasma levels of IFN-γ were elevated in all 6 monkeys.  337 
The increase in plasma levels of IL-2 was marginal by day 10 for 5 monkeys.  For 338 
inflammatory cytokines, the plasma level of MCP-1 was markedly elevated for all 339 
monkeys.  IL-4, IL-17, and IL-1β were not detected throughout the experiment.  340 
Other cytokines (IL-5, IL-6, and TNF-α) were not consistently detected (data not 341 
shown).    342 
  Taken together, there were no significant differences in the cytokine production 343 
profile between the monkeys infected with IC323-EGFP2 or EdH-EGFP2, and similar 344 
Th1-type and inflammatory response against acute MV infection have occurred in 345 
monkeys infected with IC323-EGFP2 or EdH-EGFP2.   346 
 347 
DISCUSSION 348 
  In this study, we compared the cell specificity and tropism of the wild-type strains of 349 
MV bearing the H protein of the Edmonston vaccine strain with the wild-type MV 350 
strains.  Although EdH-EGFP showed the wider cell specificity in cell lines and 351 
primary cell cultures (Fig. 1B), the tissue and organ tropism of EdH-EGFP2 was not 352 
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altered in all 5 infected macaques (Fig. 2 and 4, and Table 1).  Since CD46 is 353 
ubiquitously expressed in human and monkey cells, EdH-EGFP2 could infect all cells 354 
in macaques.  However, widespread infection of EdH-EGFP2 in tissues and organs 355 
was not observed.  This result is not surprising because it was reported that only the 356 
lymph nodes and spleen of monkeys were infected with MV vaccine strains (39).  357 
Furthermore, it was recently reported that CD11c-positive myeloid cells, such as 358 
alveolar macrophage and dendritic cells in lung of monkeys, were infected with an 359 
EGFP-expressing recombinant Edmonston strain of MV via an aerosol route (4).  360 
This result is consistent with our findings in that the CD46-using Edmonston vaccine 361 
strain does not cause widespread infection in the lungs of monkeys, although there is a 362 
possibility that the infection of Edmonston strain in lungs may be restricted due to 363 
mutations in the N and P/C/V genes which are most important in combating the innate 364 
immune system.  365 
  One possible explanation for the limited infection of EdH-EGFP2 in macaques is the 366 
expression level of CD46.  Anderson et al. reported that at low CD46 density, 367 
infection with the MV vaccine strain will occurs, but subsequent cell-to-cell fusion 368 
does not (1).  If the expression levels of CD46 are low in cells in the tissues, 369 
EdH-EGFP2 may infect those cells, but subsequent cell-to-cell fusion may not occur.  370 
In primary cell cultures, gene expression profiles often change when tissue cells are 371 
cultured in vitro.  Thus, it is likely that the CD46 expression levels of primary cell 372 
cultures are high enough for infection with EdH-EGFP.  We are now examining the 373 
expression levels of CD46 in cell lines and primary cell cultures and in tissues of 374 
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cynomolgus monkeys.  Another possibility for the limited infection of EdH-EGFP2 in 375 
macaque tissues is the inefficient replication of MV due to interferons.  Yoshikawa et 376 
al. reported that primate kidney cells rapidly lose interferon-inducing activity and 377 
permit poliovirus replication when the cells are cultured in vitro (40).  MV replication 378 
in monkey tissues may be inhibited by interferon, whereas MV replication in primary 379 
cell cultures can occur due to the lack of interferon-inducing activity. 380 
  Flow cytometric analysis showed that lymphocytes expressing SLAM were infected 381 
with both IC323-EGFP2 and EdH-EGFP2 (Fig. 6).  It is known that stimulated 382 
lymphocytes can be efficiently infected with MV and that SLAM is highly expressed 383 
in stimulated lymphocytes (11).  Thus, the activation status of lymphocytes may be 384 
important for infection with MV, and infection of unstimulated lymphocytes with 385 
EdH-EGFP2 by the CD46-mediated pathway would not result in efficient MV 386 
replication.  As a result, lymphocytes expressing SLAM may appear to be equally 387 
infected with both strains.  Recently, two groups revealed that both SLAM and CD46 388 
are required for stable transduction of resting human lymphocytes with lentiviral 389 
vectors pseudotyped with the vaccine MV F and H proteins (8, 42).  Thus, another 390 
possibility is that SLAM-binding in addition to CD46-binding may be required for 391 
efficient infection of lymphocytes with EdH-EGFP2.  SLAM-binding and subsequent 392 
signaling (8, 42) may be important for efficient MV infection. 393 
  A previous study in which monkeys were infected with pathogenic and Edmonston 394 
vaccine strains via an aerosol route showed that only the pathogenic strain caused 395 
massive infection in lymphoid tissues (4).  We also infected monkeys with 396 
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IC323-EGFP2 and EdH-EGFP2 via the aerosol route, and we found that both strains 397 
caused massive infection in lymphoid tissues (Fig. 3).  This result indicated that the 398 
Edmonston H protein does not influence the extent of infection in lymphoid tissues.  399 
Proteins other than the H protein, possibly viral polymerase proteins (30), may regulate 400 
MV replication in lymphoid tissues. 401 
  Suppression of the production of IL-12 was proposed during measles (10).  We 402 
found that the initial level of IL-12 was high for 3 monkeys (#5056, 5057, and 5062) 403 
but low for 3 monkeys (#5058, 5068, and 5069) (Fig. 7).  We do not explain the 404 
reason for this difference.  However, our results indicated that the IL-12 levels were 405 
not significantly induced at early time points during MV infection.  This result may 406 
be consistent with a previous observation of suppressed serum levels of IL-12 during 407 
MV infection in rhesus macaques (13, 26).  Interestingly, Th1-type cytokines (IFN-γ 408 
and IL-2) were induced in all monkeys irrespective of the IL-12 level.  The induction 409 
of IFN-γ in plasma at early time points is consistent with that in previous reports of 410 
human measles (10, 19, 24, 41).  A previous study showed no significant induction of 411 
IL-2, IL-12, and IFN-γ in monkeys infected with wild-type MV (5).  However, in that 412 
experiment the induction of IL-2, IL-12, and IFN-γ was measured by quantitating their 413 
mRNA by real-time RT-PCR using RNA extracted from PBMCs.  Real-time RT-PCR 414 
data may not coincide with the actual amounts of cytokines in plasma.   415 
  In summary, the current study showed that the H protein of the Edmonston vaccine 416 
strain alters the cell specificity of wild-type MV in vitro but not the tropism in 417 
macaques.  SLAM(+) cells were main target for both IC323-EGFP2 and EdH-EGFP2 418 
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in macaques.  In addition, it is suggested that the Edmonston vaccine H protein 419 
attenuates MV growth in vivo especially in a later stage.  It has long been proposed 420 
that the vaccine H protein attenuates the virus growth in vivo by several mechanisms 421 
(e.g., CD46-mediated signaling in infected cells or down-regulation of CD46 in 422 
infected cells and subsequent complement-mediated cell lysis) (14).  It will be 423 
interesting to examine the type I interferon production and the down-regulation of 424 
CD46 in MV-infected cells in monkeys infected with EdH-EGFP2 or MV vaccine 425 
strains. 426 
 427 
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FIGURE LEGENDS 619 
FIG. 1.  Generation, dissemination, and growth of recombinant measles virus 620 
(MV) having the hemagglutinin (H) protein of the Edmonston vaccine strain.  621 
(A) Schematic diagram of genomic organization of IC323-EGFP, EdH-EGFP, 622 
IC323-EGFP2, and EdH-EGFP2.  (B) B95a, Vero, primary cynomolgus monkey 623 
kidney (Primary kidney), and primary cynomolgus monkey astroglial (Primary 624 
astroglia) cells were infected with IC323-EGFP or EdH-EGFP.  The MV-infected 625 
cells were visualized with EGFP auto fluorescence at day 2 (B95a), at day 3 (Vero), at 626 
day 4 (Primary kidney) and at day 3 (Primary astroglia).  (C) Replication kinetics of 627 
IC323-EGFP2 and EdH-EGFP2.  B95a cells and Vero cells were infected with 628 
IC323-EGFP2 (circle) or EdH-EGFP2 (triangle) at an MOI of 0.01 × tissue culture 629 
infective dose (TCID50)/cell.  Cells and media were harvested at days 0, 1, 2, 3, and 4, 630 
and infectivity titers were assessed as TCID50 using B95a cells.   631 
 632 
FIG. 2.  Detection of MV-infected cells in peripheral blood mononuclear cells 633 
(PBMCs) and cervical lymph nodes and EGFP expression in the tissues and 634 
organs of infected macaques.  (A) One monkey (#4850; closed circle) was infected 635 
with IC323-EGFP2 and 2 monkeys (#4848 and #4849; open triangle and open square, 636 
respectively) were infected with EdH-EGFP2.  Single-cell suspensions (105/ml) from 637 
PBMCs and cervical lymph nodes (CLN) were divided into 2-fold serial dilutions.  638 
  30 
Then, a 1-ml aliquot of each diluted single-cell suspension was inoculated into 639 
subconfluent B95a cells on 24-well cluster plates in duplicate.  The number of 640 
MV-infected cells per 105 single-cell suspensions was then calculated.  (B) At day 7, 641 
EGFP fluorescence in the tongue and tonsils (a, e, and i), cervical lymph nodes (b, f, 642 
and j), stomach (c, g, and k), and gut-associated lymph nodes (d, h, and l), was 643 
detected using a fluorescent charge-coupled device (CCD) camera.  White arrows 644 
indicate the MV-infected regions expressing EGFP. 645 
 646 
FIG. 3.  Detection of MV-infected cells and MV genome RNA.  (A) Three 647 
monkeys (#5058, #5062, and #5069) (closed circle, closed triangle, and closed square, 648 
respectively) were infected with IC323-EGFP2, and 3 monkeys (#5056, #5057, and 649 
#5068; open circle, open triangle, and open square, respectively) were infected with 650 
EdH-EGFP2.  PBMCs were obtained at days 3, 7, and 10.  CLN and spleens were 651 
obtained on day 10.  Single-cell suspensions (105/ml) from PBMCs, CLN and spleen 652 
were divided into 2-fold serial dilutions.  Then, a 1-ml aliquot of each diluted 653 
single-cell suspension was inoculated into subconfluent B95a cells on 24-well cluster 654 
plates in duplicate.  The number of MV-infected cells per 105 single-cell suspensions 655 
was then calculated.  (B) MV genome RNA was detected by real-time reverse 656 
transcription polymerase chain reaction on total RNA isolated from tonsils, CLN, 657 
thymus, spleens, mesenteric lymph nodes (MLN), inguinal lymph nodes (IngLN), bone 658 
marrow (Bone M), and lungs.  Three monkeys (#5058, #5062 and #5069) were 659 
infected with IC323-EGFP2, and 3 monkeys (#5056, #5057, and #5068) were infected 660 
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with EdH-EGFP2.  The results for the real-time RT-PCR were expressed as genome 661 
RNA equivalent to plasmid p(+)MV323-EGFP. 662 
 663 
FIG. 4.  EGFP expression in tissues of monkeys after experimental infection with 664 
IC323-EGFP2 and EdH-EGFP2.  At day 10 days, EGFP fluorescence in the tongue 665 
and tonsils (a, f, and k), thymus (b, g, and l), trachea and lung (c, h, and m), stomach (d, 666 
i, and n), and gut-associated lymph nodes (e, j, and o) of infected monkeys were 667 
detected using a fluorescent CCD camera.   668 
 669 
FIG. 5.  Histopathological and immunohistochemical analysis.  (A) Bronchiole 670 
sections obtained from monkeys infected with IC323-EGFP2 or EdH-EGFP2 were 671 
examined by hematoxylin and eosin staining and immunohistochemistry.  Giant cell 672 
formation (*) and lymphoid filtrares were seen in the epithelial layer of the bronchiole.  673 
MV nucleocapsid (N) antigen (light brown) was detected in the cytoplasm and nucleus 674 
in the giant cells and in the cytoplasm of the lymphocytes (arrows) of lymphatic nodule 675 
under the epithelial layer by immunohistochemical analysis (IHC).  (B) Bronchiole 676 
area obtained from monkey infected with EdH-EGFP2 was investigated by double 677 
immunofluorescence staining.  Tissue sections were stained with antiserum against 678 
the MV N antigen and mouse monoclonal antibody against cytokeratin.  DAPI was 679 
used to identify nuclei.  Br, Bronchiole; LN, lymphatic nodule; Bar, A, 50 µm; B, 100 680 
µm. 681 
 682 
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FIG. 6.  EGFP-positive cells in lymphocyte subpopulations of PBMCs and 683 
mesenteric lymph nodes from infected monkeys.  (A) Cryopreserved PBMCs and 684 
mesenteric lymph nodes (MLN) of monkeys infected with IC323-EGFP2 (#5058) or 685 
EdH-EGFP2 (#5057 and #5068) were stained with monoclonal antibodies against CD3, 686 
CD20 and CD150 (signaling lymphocyte activation molecule; SLAM), and analyzed in 687 
a FACScalibur.  Results are shown as dot plots, with SLAM expression on the x-axis 688 
and EGFP expression on the y-axis.  EGFP expression in CD20+ B-lymphocytes and 689 
CD3+ T-lymphocytes are shown.  (B) CD46 expression in lymphocytes of PBMCs of 690 
monkeys infected with EdH-EGFP2 (#5057 and #5068) was detected with monoclonal 691 
antibody against CD46 and isotype control antibody. 692 
 693 
FIG. 7.  Detection of cytokines in the plasma of infected monkeys.  Three 694 
monkeys (#5058, #5062, and #5069; closed circle, closed triangle and closed square, 695 
respectively) were infected with IC323-EGFP2.  Three monkeys (#5056, #5057, and 696 
#5068; open circle, open triangle and open square, respectively) were infected with 697 
EdH-EGFP2.  Plasma was obtained at days 0, 3, 7, and 10.  Cytokine levels in the 698 
plasma were measured with a Luminex 200 using a Milliplex Non-Human Primate 699 
Cytokine/Chemokine kit.  The physiological upper concentration ranges detected in 700 
human plasma are indicated by dotted lines. 701 
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